Across TCGA pan-cancer cohorts, SLIT1-AS1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SLIT1-AS1’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where SLIT1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLIT1-AS1 is over-expressed in tumor.
THCA and PRAD are the cancer types where SLIT1-AS1 tumor–normal differential expression is most reproducible.